Summary of Study ST002484

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001606. The data can be accessed directly via it's Project DOI: 10.21228/M83T4M This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002484
Study TitleMetabolomic analysis of maternal mid-gestation plasma and cord blood: primary metabolism
Study SummaryMetabolomic analysis of maternal mid-gestation plasma and cord blood reveals evidence in autism spectrum disorder of inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. The discovery of prenatal and neonatal molecular biomarkers has the potential to yield insights into autism spectrum disorder (ASD) and facilitate early diagnosis. We characterized metabolomic profiles in ASD using plasma samples collected in the Norwegian Autism Birth Cohort from mothers at weeks 17-21 gestation (maternal mid-gestation, MMG, n=408) and from children on the day of birth (cord blood, CB, n=418). We analyzed associations using sex-stratified adjusted logistic regression models with Bayesian analyses. Chemical enrichment analyses (ChemRICH) were performed to determine altered chemical clusters. We also employed machine learning algorithms to assess the utility of metabolomics as ASD biomarkers. We identified ASD associations with a variety of chemical compounds including arachidonic acid, glutamate, and glutamine, and metabolite clusters including hydroxy eicospentaenoic acids, phosphatidylcholines, and ceramides in MMG and CB plasma that are consistent with inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. Girls with ASD have disruption of ether/non-ether phospholipid balance in the MMG plasma that is similar to that found in other neurodevelopmental disorders. ASD boys in the CB analyses had the highest number of dysregulated chemical clusters. Machine learning classifiers distinguished ASD cases from controls with AUC values ranging from 0.710 to 0.853. Predictive performance was better in CB analyses than in MMG. These findings may provide new insights into the sex-specific differences in ASD and have implications for discovery of biomarkers that may enable early diagnosis and intervention.
Institute
Columbia University
Last NameLipkin
First NameW. Ian
Address722 W. 168th St., 17th Floor, New York, NY, 10032
Emailwil2001@cumc.columbia.edu
Phone(212) 342-9033
Submit Date2023-02-21
Raw Data AvailableYes
Raw Data File Type(s)cdf
Analysis Type DetailGC-MS
Release Date2023-07-02
Release Version1
W. Ian Lipkin W. Ian Lipkin
https://dx.doi.org/10.21228/M83T4M
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001606
Project DOI:doi: 10.21228/M83T4M
Project Title:Metabolomic analysis of maternal mid-gestation plasma and cord blood
Project Summary:Metabolomic analysis of maternal mid-gestation plasma and cord blood reveals evidence in autism spectrum disorder of inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. The discovery of prenatal and neonatal molecular biomarkers has the potential to yield insights into autism spectrum disorder (ASD) and facilitate early diagnosis. We characterized metabolomic profiles in ASD using plasma samples collected in the Norwegian Autism Birth Cohort from mothers at weeks 17-21 gestation (maternal mid-gestation, MMG, n=408) and from children on the day of birth (cord blood, CB, n=418). We analyzed associations using sex-stratified adjusted logistic regression models with Bayesian analyses. Chemical enrichment analyses (ChemRICH) were performed to determine altered chemical clusters. We also employed machine learning algorithms to assess the utility of metabolomics as ASD biomarkers. We identified ASD associations with a variety of chemical compounds including arachidonic acid, glutamate, and glutamine, and metabolite clusters including hydroxy eicospentaenoic acids, phosphatidylcholines, and ceramides in MMG and CB plasma that are consistent with inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. Girls with ASD have disruption of ether/non-ether phospholipid balance in the MMG plasma that is similar to that found in other neurodevelopmental disorders. ASD boys in the CB analyses had the highest number of dysregulated chemical clusters. Machine learning classifiers distinguished ASD cases from controls with AUC values ranging from 0.710 to 0.853. Predictive performance was better in CB analyses than in MMG. These findings may provide new insights into the sex-specific differences in ASD and have implications for discovery of biomarkers that may enable early diagnosis and intervention.
Institute:Columbia University
Department:Center for Infection and Immunity
Laboratory:Center for Infection and Immunity
Last Name:Lipkin
First Name:W. Ian
Address:722 W. 168th St., 17th Floor, New York, NY, 10032
Email:wil2001@cumc.columbia.edu
Phone:(212) 342-9033

Subject:

Subject ID:SU002804
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sex
SA269536ABC-17438_315Female | Diagnosis:CASE
SA269537ABC-19850_538Female | Diagnosis:CASE
SA269538ABC-17316_307Female | Diagnosis:CASE
SA269539ABC-17926_418Female | Diagnosis:CASE
SA269540ABC-19930_264Female | Diagnosis:CASE
SA269541ABC-19926_722Female | Diagnosis:CASE
SA269542ABC-19756_272Female | Diagnosis:CASE
SA269543ABC-19881_776Female | Diagnosis:CASE
SA269544ABC-19714_984Female | Diagnosis:CASE
SA269545ABC-10358_478Female | Diagnosis:CASE
SA269546ABC-9987_885Female | Diagnosis:CASE
SA269547ABC-19205_624Female | Diagnosis:CASE
SA269548ABC-19210_658Female | Diagnosis:CASE
SA269549ABC-18865_686Female | Diagnosis:CASE
SA269550ABC-19283_383Female | Diagnosis:CASE
SA269551ABC-17760_948Female | Diagnosis:CASE
SA269552ABC-19202_238Female | Diagnosis:CASE
SA269553ABC-19047_503Female | Diagnosis:CASE
SA269554ABC-17759_615Female | Diagnosis:CASE
SA269555ABC-19050_632Female | Diagnosis:CASE
SA269556ABC-17697_966Female | Diagnosis:CASE
SA269557ABC-17671_849Female | Diagnosis:CASE
SA269558ABC-10032_831Female | Diagnosis:CASE
SA269559ABC-18778_694Female | Diagnosis:CASE
SA269560ABC-18738_564Female | Diagnosis:CASE
SA269561ABC-18908_221Female | Diagnosis:CASE
SA269562ABC-17540_605Female | Diagnosis:CASE
SA269563ABC-19574_256Female | Diagnosis:CASE
SA269564ABC-19632_857Female | Diagnosis:CASE
SA269565ABC-19465_469Female | Diagnosis:CASE
SA269566ABC-19458_712Female | Diagnosis:CASE
SA269567ABC-19407_785Female | Diagnosis:CASE
SA269568ABC-18756_323Female | Diagnosis:CASE
SA269569ABC-7113_358Female | Diagnosis:CASE
SA269570ABC-19438_730Female | Diagnosis:CASE
SA269571ABC-17482_374Female | Diagnosis:CASE
SA269572ABC-16983_1018Female | Diagnosis:CASE
SA269573ABC-16466_246Female | Diagnosis:CASE
SA269574ABC-21723_921Female | Diagnosis:CASE
SA269575ABC-4191_443Female | Diagnosis:CASE
SA269576ABC-16430_821Female | Diagnosis:CASE
SA269577ABC-21823_513Female | Diagnosis:CASE
SA269578ABC-2180_487Female | Diagnosis:CASE
SA269579ABC-4344_332Female | Diagnosis:CASE
SA269580ABC-16602_893Female | Diagnosis:CASE
SA269581ABC-21479_903Female | Diagnosis:CASE
SA269582ABC-21476_348Female | Diagnosis:CASE
SA269583ABC-20046_451Female | Diagnosis:CASE
SA269584ABC-21537_554Female | Diagnosis:CASE
SA269585ABC-21684_495Female | Diagnosis:CASE
SA269586ABC-16673_929Female | Diagnosis:CASE
SA269587ABC-11191_867Female | Diagnosis:CASE
SA269588ABC-16329_521Female | Diagnosis:CASE
SA269589ABC-2332_813Female | Diagnosis:CASE
SA269590ABC-3185_230Female | Diagnosis:CASE
SA269591ABC-3138_409Female | Diagnosis:CASE
SA269592ABC-11725_580Female | Diagnosis:CASE
SA269593ABC-2881_650Female | Diagnosis:CASE
SA269594ABC-11634_461Female | Diagnosis:CASE
SA269595ABC-11918_1010Female | Diagnosis:CASE
SA269596ABC-2299_640Female | Diagnosis:CASE
SA269597ABC-21970_758Female | Diagnosis:CASE
SA269598ABC-3681_529Female | Diagnosis:CASE
SA269599ABC-2200_426Female | Diagnosis:CASE
SA269600ABC-2262_958Female | Diagnosis:CASE
SA269601ABC-2298_205Female | Diagnosis:CASE
SA269602ABC-3414_546Female | Diagnosis:CASE
SA269603ABC-16796_911Female | Diagnosis:CASE
SA269604ABC-21528_366Female | Diagnosis:CASE
SA269605ABC-20903_391Female | Diagnosis:CASE
SA269606ABC-20900_795Female | Diagnosis:CASE
SA269607ABC-5666_766Female | Diagnosis:CASE
SA269608ABC-21379_213Female | Diagnosis:CASE
SA269609ABC-20953_748Female | Diagnosis:CASE
SA269610ABC-20952_572Female | Diagnosis:CASE
SA269611ABC-20870_589Female | Diagnosis:CASE
SA269612ABC-20867_994Female | Diagnosis:CASE
SA269613ABC-20769_597Female | Diagnosis:CASE
SA269614ABC-20531_289Female | Diagnosis:CASE
SA269615ABC-20792_1002Female | Diagnosis:CASE
SA269616ABC-17221_668Female | Diagnosis:CASE
SA269617ABC-20853_803Female | Diagnosis:CASE
SA269618ABC-5893_875Female | Diagnosis:CASE
SA269619ABC-20956_340Female | Diagnosis:CASE
SA269620ABC-20950_976Female | Diagnosis:CASE
SA269621ABC-21073_839Female | Diagnosis:CASE
SA269622ABC-16993_740Female | Diagnosis:CASE
SA269623ABC-21076_435Female | Diagnosis:CASE
SA269624ABC-16904_676Female | Diagnosis:CASE
SA269625ABC-21318_399Female | Diagnosis:CASE
SA269626ABC-16997_281Female | Diagnosis:CASE
SA269627ABC-2836_939Female | Diagnosis:CASE
SA269628ABC-21004_704Female | Diagnosis:CASE
SA269629ABC-21007_297Female | Diagnosis:CASE
SA269630ABC-8388_840Female | Diagnosis:CONTROL
SA269631ABC-8876_1003Female | Diagnosis:CONTROL
SA269632ABC-9061_651Female | Diagnosis:CONTROL
SA269633ABC-8355_452Female | Diagnosis:CONTROL
SA269634ABC-8614_539Female | Diagnosis:CONTROL
SA269635ABC-9565_341Female | Diagnosis:CONTROL
Showing page 1 of 10     Results:    1  2  3  4  5  Next  Last     Showing results 1 to 100 of 918

Collection:

Collection ID:CO002797
Collection Summary:Spun inside centrifuge and processed
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR002813
Treatment Summary:NA

Sample Preparation:

Sampleprep ID:SP002810
Sampleprep Summary:SOP blood-LCGCextract-02252019
Sampleprep Protocol Filename:SOP_blood-LCGCextract-02252019.docx

Combined analysis:

Analysis ID AN004375
Analysis type MS
Chromatography type GC
Chromatography system Agilent 7890 GC- Pegasus IV TOF MS
Column Restek Rtx-5Sil MS (30m x 0.25mm, 0.25um)
MS Type EI
MS instrument type GC-TOF
MS instrument name Leco Pegasus IV TOF
Ion Mode POSITIVE
Units normalized peak heights

Chromatography:

Chromatography ID:CH003281
Instrument Name:Agilent 7890 GC- Pegasus IV TOF MS
Column Name:Restek Rtx-5Sil MS (30m x 0.25mm, 0.25um)
Column Temperature:NA
Flow Gradient:NA
Flow Rate:1 mL/min
Solvent A:NA
Solvent B:NA
Chromatography Type:GC

MS:

MS ID:MS004124
Analysis ID:AN004375
Instrument Name:Leco Pegasus IV TOF
Instrument Type:GC-TOF
MS Type:EI
MS Comments:Mass spectrometer settings: A Leco Pegasus IV time of flight mass spectrometer is controlled by the Leco ChromaTOF software vs. 2.32 (St. Joseph, MI). The transfer line temperature between gas chromatograph and mass spectrometer is set to 280°C. Electron impact ionization at 70V is employed with an ion source temperature of 250°C. Acquisition rate is 17 spectra/second, with a scan mass range of 85-500 Da.
Ion Mode:POSITIVE
  logo